Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants
After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlle...
Saved in:
| Published in | Journal of comparative effectiveness research Vol. 9; no. 9; pp. 603 - 614 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Future Medicine Ltd
01.06.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2042-6305 2042-6313 2042-6313 |
| DOI | 10.2217/cer-2020-0013 |
Cover
| Abstract | After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlled trials. Comparative effectiveness research of OACs based on real-world data provides complementary information to randomized controlled trials. Propensity score matching and inverse probability of treatment weighting are increasingly popular methods used to address confounding by indication potentially arising in comparative effectiveness research due to a lack of randomization in treatment assignment. This review describes the fundamentals of propensity score matching and inverse probability of treatment weighting, appraises differences between them and presents applied examples to elevate understanding of these methods within the atrial fibrillation field. |
|---|---|
| AbstractList | After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlled trials. Comparative effectiveness research of OACs based on real-world data provides complementary information to randomized controlled trials. Propensity score matching and inverse probability of treatment weighting are increasingly popular methods used to address confounding by indication potentially arising in comparative effectiveness research due to a lack of randomization in treatment assignment. This review describes the fundamentals of propensity score matching and inverse probability of treatment weighting, appraises differences between them and presents applied examples to elevate understanding of these methods within the atrial fibrillation field. After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlled trials. Comparative effectiveness research of OACs based on real-world data provides complementary information to randomized controlled trials. Propensity score matching and inverse probability of treatment weighting are increasingly popular methods used to address confounding by indication potentially arising in comparative effectiveness research due to a lack of randomization in treatment assignment. This review describes the fundamentals of propensity score matching and inverse probability of treatment weighting, appraises differences between them and presents applied examples to elevate understanding of these methods within the atrial fibrillation field.After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban, dabigatran, edoxaban and rivaroxaban) were approved after demonstrating noninferior efficacy and safety versus warfarin in randomized controlled trials. Comparative effectiveness research of OACs based on real-world data provides complementary information to randomized controlled trials. Propensity score matching and inverse probability of treatment weighting are increasingly popular methods used to address confounding by indication potentially arising in comparative effectiveness research due to a lack of randomization in treatment assignment. This review describes the fundamentals of propensity score matching and inverse probability of treatment weighting, appraises differences between them and presents applied examples to elevate understanding of these methods within the atrial fibrillation field. |
| Author | Jenkins, Aaron Mardekian, Jack Luo, Xuemei Ramagopalan, Sreeram V Allan, Victoria Pan, Xianying Li, Xiaoyan |
| AuthorAffiliation | 2Statistics, Global Biometrics and Data Management, Pfizer Inc., New York City, NY, USA 4Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA 6Patient Health & Impact, Outcomes & Evidence, Pfizer Inc., Groton, CT, USA 3Patient Health & Impact, Outcomes & Evidence, Pfizer Ltd, Tadworth, UK 5Pharmacoepidemiology, Bristol-Myers Squibb, Lawrenceville, NJ, USA 1Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK |
| AuthorAffiliation_xml | – name: 5Pharmacoepidemiology, Bristol-Myers Squibb, Lawrenceville, NJ, USA – name: 2Statistics, Global Biometrics and Data Management, Pfizer Inc., New York City, NY, USA – name: 4Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA – name: 6Patient Health & Impact, Outcomes & Evidence, Pfizer Inc., Groton, CT, USA – name: 1Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK – name: 3Patient Health & Impact, Outcomes & Evidence, Pfizer Ltd, Tadworth, UK |
| Author_xml | – sequence: 1 givenname: Victoria orcidid: 0000-0002-3284-8896 surname: Allan fullname: Allan, Victoria organization: Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK – sequence: 2 givenname: Sreeram V surname: Ramagopalan fullname: Ramagopalan, Sreeram V organization: Centre for Observational Research & Data Sciences, Bristol-Myers Squibb, Uxbridge, UK – sequence: 3 givenname: Jack surname: Mardekian fullname: Mardekian, Jack organization: Statistics, Global Biometrics and Data Management, Pfizer Inc., New York City, NY, USA – sequence: 4 givenname: Aaron surname: Jenkins fullname: Jenkins, Aaron organization: Patient Health & Impact, Outcomes & Evidence, Pfizer Ltd, Tadworth, UK – sequence: 5 givenname: Xiaoyan surname: Li fullname: Li, Xiaoyan organization: Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb, Lawrenceville, NJ, USA – sequence: 6 givenname: Xianying surname: Pan fullname: Pan, Xianying organization: Pharmacoepidemiology, Bristol-Myers Squibb, Lawrenceville, NJ, USA – sequence: 7 givenname: Xuemei surname: Luo fullname: Luo, Xuemei organization: Patient Health & Impact, Outcomes & Evidence, Pfizer Inc., Groton, CT, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32186922$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkUtv1TAUhC1UREvpki2yxIZNih953CxRxUuqBAtYW459fK-rxA620-r-JX4lJ6R0UanCm4zjb-zx-CU5CTEAIa85uxSCd-8NpEowwSrGuHxGzgSrRdVKLk8eNGtOyUXONwxHu6v7Rrwgp1LwXdsLcUZ-f09xhpB9OdJsYgI66WIOPuypDpb6cAspA51THPTgxxWLjpYEukwQCr0Dvz-UFS-RamsT5ExNDC4uwa6_hyNuYr3RxceAEhenWSec3gIF58CsKqw29IJO5rCeEJMeMUHxJur9MqLKr8hzp8cMF_ffc_Lz08cfV1-q62-fv159uK5MzVmpHOtR7Jju5c6aoe2ZGJpWtE0zMOtq6AGYs7rvmJCO2W4nZO1q3vHOCoY2eU4ut32XMOvjnR5HNSc_6XRUnKm1d4W9q7V3tfaOhnebAVv6tUAuavLZwIipIS5ZCdlhCN62HaJvH6E3cUkBr6NEwzreNFIKpN7cU8swgX04_t-zISA3wKSYcwKnjC9_Gy5J-_HJnNUj1__u1W-8W8qCj2M8BANqm2Eub3yAJ7x_AGx90bA |
| CitedBy_id | crossref_primary_10_1093_geront_gnab184 crossref_primary_10_1038_s41390_023_02836_3 crossref_primary_10_1016_j_amjmed_2024_02_005 crossref_primary_10_1371_journal_pone_0305526 crossref_primary_10_1177_10600280241237781 crossref_primary_10_1093_ajcn_nqab244 crossref_primary_10_1007_s10557_023_07521_5 crossref_primary_10_1001_jamaophthalmol_2024_1204 crossref_primary_10_3390_cancers13133231 crossref_primary_10_1016_j_prevetmed_2024_106165 crossref_primary_10_1002_ana_26451 crossref_primary_10_1212_WNL_0000000000208114 crossref_primary_10_1016_j_jsat_2021_108503 crossref_primary_10_1038_s41531_025_00870_y crossref_primary_10_3389_fphar_2021_812018 crossref_primary_10_1016_j_lungcan_2023_107280 crossref_primary_10_1186_s12978_022_01442_6 crossref_primary_10_1007_s41666_023_00153_2 crossref_primary_10_1097_GOX_0000000000004003 crossref_primary_10_1001_jamasurg_2025_0108 crossref_primary_10_3389_fpsyt_2022_1033328 crossref_primary_10_1007_s12325_024_03068_5 crossref_primary_10_2147_COPD_S370540 crossref_primary_10_1007_s10928_024_09950_7 crossref_primary_10_1016_j_semarthrit_2021_07_004 crossref_primary_10_1245_s10434_022_11898_2 crossref_primary_10_1038_s41598_022_16984_9 crossref_primary_10_1007_s40615_024_02144_4 crossref_primary_10_1093_ehjopen_oeae016 crossref_primary_10_1007_s40121_021_00516_5 crossref_primary_10_1080_10543406_2021_2011901 crossref_primary_10_1080_10543406_2021_2011904 crossref_primary_10_1007_s44162_024_00057_8 crossref_primary_10_1016_j_jagp_2025_02_005 crossref_primary_10_3390_ijerph191912916 crossref_primary_10_1093_ehjcvp_pvad070 crossref_primary_10_1016_j_sapharm_2024_08_004 crossref_primary_10_1001_jamasurg_2024_2116 crossref_primary_10_1007_s00134_022_06966_w crossref_primary_10_1016_j_ijantimicag_2023_106817 crossref_primary_10_1093_ehjcvp_pvac058 crossref_primary_10_2147_PPA_S440410 crossref_primary_10_1080_09645292_2021_1951172 crossref_primary_10_1177_19476035241247700 crossref_primary_10_1002_jso_26664 crossref_primary_10_1038_s41598_023_47896_x crossref_primary_10_1017_ice_2021_381 crossref_primary_10_1016_j_jad_2023_07_019 crossref_primary_10_1136_jech_2023_220891 crossref_primary_10_1186_s13613_023_01183_0 crossref_primary_10_1080_02770903_2022_2089995 crossref_primary_10_1097_JS9_0000000000000487 crossref_primary_10_1016_j_jad_2025_03_079 crossref_primary_10_3390_ph17020178 crossref_primary_10_1177_14799731241310897 crossref_primary_10_1055_a_1731_3922 crossref_primary_10_1016_j_brs_2021_05_010 crossref_primary_10_1016_j_jns_2021_117364 crossref_primary_10_1002_jpen_2729 crossref_primary_10_1111_odi_14658 crossref_primary_10_1007_s40119_023_00316_7 crossref_primary_10_1142_S2424835524500206 crossref_primary_10_1016_j_healthpol_2022_03_009 crossref_primary_10_1161_STROKEAHA_124_049278 crossref_primary_10_1161_STROKEAHA_124_049038 crossref_primary_10_3390_medicina58010063 crossref_primary_10_1001_jamanetworkopen_2021_26306 crossref_primary_10_1002_clc_70064 crossref_primary_10_36096_ijbes_v6i5_629 crossref_primary_10_1016_j_jor_2024_03_020 crossref_primary_10_1002_jso_27141 crossref_primary_10_1097_CCM_0000000000005932 crossref_primary_10_3390_nu15184067 crossref_primary_10_1186_s40560_022_00622_7 crossref_primary_10_1097_j_pain_0000000000003448 crossref_primary_10_1136_oemed_2022_108670 crossref_primary_10_2217_cer_2021_0249 crossref_primary_10_1016_j_jamda_2023_11_010 crossref_primary_10_1007_s10499_021_00799_y crossref_primary_10_1371_journal_pone_0291057 crossref_primary_10_1038_s41598_024_58608_4 crossref_primary_10_1016_j_jnma_2024_10_009 crossref_primary_10_1038_s41591_022_01969_y crossref_primary_10_5468_ogs_22146 crossref_primary_10_1053_j_gastro_2022_08_054 crossref_primary_10_1371_journal_pone_0277744 crossref_primary_10_3389_fphar_2023_1096999 crossref_primary_10_1080_1744666X_2023_2294040 crossref_primary_10_1038_s41598_022_14856_w crossref_primary_10_1016_j_amjms_2022_01_021 crossref_primary_10_1016_j_chiabu_2023_106512 crossref_primary_10_1016_j_jval_2022_09_2480 crossref_primary_10_2217_cer_2020_0244 crossref_primary_10_1080_13696998_2021_1890428 crossref_primary_10_1002_alz_14373 crossref_primary_10_1016_j_jtho_2023_12_021 crossref_primary_10_1038_s41746_024_01175_9 crossref_primary_10_1002_sd_2701 crossref_primary_10_1136_rmdopen_2021_001601 crossref_primary_10_1161_STROKEAHA_120_031007 crossref_primary_10_2217_cer_2021_0224 crossref_primary_10_5527_wjn_v12_i5_132 crossref_primary_10_1111_aas_70026 crossref_primary_10_1186_s12931_021_01857_y crossref_primary_10_57264_cer_2023_0026 crossref_primary_10_1136_bmjopen_2023_079341 crossref_primary_10_1158_2643_3230_BCD_24_0052 crossref_primary_10_7759_cureus_55825 crossref_primary_10_5534_wjmh_220179 |
| Cites_doi | 10.1002/sim.5753 10.1093/aje/kwg115 10.1007/s40264-016-0480-3 10.1093/biomet/70.1.41 10.1056/NEJMoa0905561 10.1016/j.cjca.2015.05.015 10.1002/pst.433 10.1002/sim.6607 10.1111/j.1524-4733.2009.00671.x 10.1016/j.jtcvs.2007.07.021 10.1253/circj.CJ-18-0535 10.1002/sim.6004 10.1093/aje/kwq224 10.1161/CIRCULATIONAHA.105.595140 10.2147/JMDH.S160029 10.1056/NEJMoa1107039 10.1056/NEJMoa1009638 10.1093/aje/kwq439 10.1002/pds.3263 10.2217/cer.13.89 10.1016/j.cct.2011.05.006 10.1111/j.1524-4733.2009.00602.x 10.1214/09-STS313 10.1161/CIRCULATIONAHA.113.005119 10.1056/NEJMoa1310907 10.1136/bmj.i3189 10.1001/jama.2016.16435 10.1136/emj.20.2.164 10.1007/s10654-018-0415-7 10.1161/CIRCOUTCOMES.119.006065 10.1136/rmdopen-2019-000953 10.1002/pds.4297 10.1136/bmj.i4919 10.1080/00273171.2011.568786 10.1136/bmj.l5657 10.1007/s40471-013-0004-y 10.2217/cer-2018-0007 10.1161/STROKEAHA.118.020232 10.1093/aje/kww165 10.1016/j.jacc.2016.10.060 10.7326/0003-4819-146-12-200706190-00007 10.1111/j.1742-7843.2006.pto_293.x 10.1136/bmj.j510 |
| ContentType | Journal Article |
| Copyright | 2020 Victoria Allan 2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 Victoria Allan – notice: 2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | FUMOA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS 7X8 ADTOC UNPAY |
| DOI | 10.2217/cer-2020-0013 |
| DatabaseName | Future Medicine (Open Access) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Proquest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic ProQuest One Academic Eastern Edition |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: FUMOA name: Future Medicine (Open Access) url: https://www.futuremedicine.com/action/showPublications?pubType=journal sourceTypes: Publisher – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2042-6313 |
| EndPage | 614 |
| ExternalDocumentID | 10.2217/cer-2020-0013 32186922 10_2217_cer_2020_0013 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GroupedDBID | 0R 3V. 53G 70G 7X7 8FI 8FJ ABUWG ADBBV AENEX AFKRA ALMA_UNASSIGNED_HOLDINGS BBAFP BENPR BPHCQ BVXVI EBS FUMOA FYUFA HZ IAO IHR NTCAX O9- PQEST PQQKQ PROAC RFM 4.4 AAWTO AAYXX CCPQU CITATION EJD GROUPED_DOAJ H13 HMCUK HZ~ ITC OVD PHGZM RPM TEORI UKHRP ALIPV CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PQUKI PRINS 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c410t-f09c4180a938dcb6902b562655b0df4e9ee0fda97023f0d78234f41717d2080a3 |
| IEDL.DBID | FUMOA |
| ISSN | 2042-6305 2042-6313 |
| IngestDate | Sun Sep 07 11:22:06 EDT 2025 Sun Sep 28 09:09:20 EDT 2025 Mon Jun 30 06:38:28 EDT 2025 Mon Jul 21 05:57:50 EDT 2025 Wed Oct 01 03:07:19 EDT 2025 Thu Apr 24 22:56:08 EDT 2025 Tue Jan 05 21:37:46 EST 2021 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | confounding by indication comparative effectiveness research atrial fibrillation propensity score matching inverse probability of treatment weighting oral anticoagulants |
| Language | English |
| License | cc-by-nc-nd |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c410t-f09c4180a938dcb6902b562655b0df4e9ee0fda97023f0d78234f41717d2080a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-3284-8896 |
| OpenAccessLink | http://dx.doi.org/10.2217/cer-2020-0013 |
| PMID | 32186922 |
| PQID | 2507155332 |
| PQPubID | 3747994 |
| PageCount | 12 |
| ParticipantIDs | unpaywall_primary_10_2217_cer_2020_0013 proquest_miscellaneous_2379021667 proquest_journals_2507155332 pubmed_primary_32186922 crossref_citationtrail_10_2217_cer_2020_0013 crossref_primary_10_2217_cer_2020_0013 futurescience_futuremedicine_10_2217_cer_2020_0013 |
| ProviderPackageCode | RFM FUMOA NTCAX 70G CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-01 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of comparative effectiveness research |
| PublicationTitleAlternate | J Comp Eff Res |
| PublicationYear | 2020 |
| Publisher | Future Medicine Ltd |
| Publisher_xml | – name: Future Medicine Ltd |
| References | Nielsen PB (e_1_3_4_38_2) 2017; 356 Sterne JA (e_1_3_4_15_2) 2016; 355 Biondi-Zoccai G (e_1_3_4_20_2) 2011; 32 Rassen JA (e_1_3_4_43_2) 2012; 21 Chugh SS (e_1_3_4_3_2) 2014; 129 Glynn RJ (e_1_3_4_22_2) 2006; 98 Kyriacou DN (e_1_3_4_17_2) 2016; 316 Lip GYH (e_1_3_4_25_2) 2018; 49 Li G (e_1_3_4_14_2) 2019; 34 Hart RG (e_1_3_4_6_2) 2007; 146 Katkade VB (e_1_3_4_13_2) 2018; 11 Larsen TB (e_1_3_4_27_2) 2016; 353 Joseph KS (e_1_3_4_16_2) 2014; 1 Rosenbaum PR (e_1_3_4_28_2) 1983; 70 Cepeda MS (e_1_3_4_23_2) 2003; 158 Patel MR (e_1_3_4_10_2) 2011; 365 Ganjehei L (e_1_3_4_5_2) 2011; 38 Bergstra SA (e_1_3_4_44_2) 2019; 5 Miyasaka Y (e_1_3_4_4_2) 2006; 114 Connolly SJ (e_1_3_4_8_2) 2009; 361 Johnson ML (e_1_3_4_45_2) 2009; 12 Li X (e_1_3_4_35_2) 2020; 13 Deb S (e_1_3_4_36_2) 2016; 32 Giugliano RP (e_1_3_4_9_2) 2013; 369 Stuart EA (e_1_3_4_41_2) 2010; 25 Austin PC (e_1_3_4_29_2) 2011; 46 Schuler MS (e_1_3_4_48_2) 2017; 185 Austin PC (e_1_3_4_46_2) 2015; 34 Elze MC (e_1_3_4_21_2) 2017; 69 Seeger JD (e_1_3_4_24_2) 2017; 40 e_1_3_4_30_2 Okumura Y (e_1_3_4_26_2) 2018; 82 Austin PC (e_1_3_4_39_2) 2014; 33 Austin PC (e_1_3_4_42_2) 2011; 10 Mccaffrey DF (e_1_3_4_47_2) 2013; 32 e_1_3_4_32_2 e_1_3_4_31_2 Desai RJ (e_1_3_4_37_2) 2019; 367 e_1_3_4_19_2 Xu S (e_1_3_4_49_2) 2010; 13 Austin PC (e_1_3_4_33_2) 2007; 134 Funk MJ (e_1_3_4_34_2) 2011; 173 Kendall JM (e_1_3_4_11_2) 2003; 20 e_1_3_4_18_2 Granger CB (e_1_3_4_7_2) 2011; 365 Berger ML (e_1_3_4_12_2) 2017; 26 Austin PC (e_1_3_4_40_2) 2010; 172 |
| References_xml | – volume: 32 start-page: 3388 issue: 19 year: 2013 ident: e_1_3_4_47_2 article-title: A tutorial on propensity score estimation for multiple treatments using generalized boosted models publication-title: Stat. Med. doi: 10.1002/sim.5753 – volume: 158 start-page: 280 issue: 3 year: 2003 ident: e_1_3_4_23_2 article-title: Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kwg115 – volume: 40 start-page: 169 issue: 2 year: 2017 ident: e_1_3_4_24_2 article-title: Propensity score weighting compared to matching in a study of dabigatran and warfarin publication-title: Drug Saf. doi: 10.1007/s40264-016-0480-3 – volume: 70 start-page: 41 issue: 1 year: 1983 ident: e_1_3_4_28_2 article-title: The central role of the propensity score in observational studies for causal effects publication-title: Biometrika doi: 10.1093/biomet/70.1.41 – ident: e_1_3_4_31_2 – volume: 361 start-page: 1139 issue: 12 year: 2009 ident: e_1_3_4_8_2 article-title: Dabigatran versus warfarin in patients with atrial fibrillation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0905561 – volume: 32 start-page: 259 issue: 2 year: 2016 ident: e_1_3_4_36_2 article-title: A review of propensity-score methods and their use in cardiovascular research publication-title: Can. J. Cardiol. doi: 10.1016/j.cjca.2015.05.015 – volume: 10 start-page: 150 issue: 2 year: 2011 ident: e_1_3_4_42_2 article-title: Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies publication-title: Pharmaceut. Stat. doi: 10.1002/pst.433 – volume: 34 start-page: 3661 issue: 28 year: 2015 ident: e_1_3_4_46_2 article-title: Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies publication-title: Stat. Med. doi: 10.1002/sim.6607 – volume: 13 start-page: 273 issue: 2 year: 2010 ident: e_1_3_4_49_2 article-title: Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals publication-title: Value Health doi: 10.1111/j.1524-4733.2009.00671.x – volume: 134 start-page: 1128 issue: 5 year: 2007 ident: e_1_3_4_33_2 article-title: Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: a systematic review and suggestions for improvement publication-title: J. Thoracic Cardiovasc. Surg. doi: 10.1016/j.jtcvs.2007.07.021 – volume: 82 start-page: 2500 issue: 10 year: 2018 ident: e_1_3_4_26_2 article-title: Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation-findings from the SAKURA AF registry publication-title: Circulation doi: 10.1253/circj.CJ-18-0535 – volume: 33 start-page: 1057 issue: 6 year: 2014 ident: e_1_3_4_39_2 article-title: A comparison of 12 algorithms for matching on the propensity score publication-title: Stat. Med. doi: 10.1002/sim.6004 – volume: 172 start-page: 1092 issue: 9 year: 2010 ident: e_1_3_4_40_2 article-title: Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kwq224 – volume: 114 start-page: 119 issue: 2 year: 2006 ident: e_1_3_4_4_2 article-title: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.105.595140 – volume: 11 start-page: 295 year: 2018 ident: e_1_3_4_13_2 article-title: Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making publication-title: J. Multidisciplin. Healthcare doi: 10.2147/JMDH.S160029 – volume: 365 start-page: 981 issue: 11 year: 2011 ident: e_1_3_4_7_2 article-title: Apixaban versus warfarin in patients with atrial fibrillation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1107039 – volume: 365 start-page: 883 issue: 10 year: 2011 ident: e_1_3_4_10_2 article-title: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1009638 – ident: e_1_3_4_30_2 – volume: 173 start-page: 761 issue: 7 year: 2011 ident: e_1_3_4_34_2 article-title: Doubly robust estimation of causal effects publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kwq439 – volume: 21 start-page: 69 issue: 2 year: 2012 ident: e_1_3_4_43_2 article-title: One-to-many propensity score matching in cohort studies publication-title: Pharmacoepidemiol. Drug Saf. doi: 10.1002/pds.3263 – ident: e_1_3_4_19_2 doi: 10.2217/cer.13.89 – volume: 32 start-page: 731 issue: 5 year: 2011 ident: e_1_3_4_20_2 article-title: Are propensity scores really superior to standard multivariable analysis? publication-title: Contemp. Clin. Trials doi: 10.1016/j.cct.2011.05.006 – volume: 12 start-page: 1062 issue: 8 year: 2009 ident: e_1_3_4_45_2 article-title: Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part III publication-title: Value Health doi: 10.1111/j.1524-4733.2009.00602.x – volume: 25 start-page: 1 issue: 1 year: 2010 ident: e_1_3_4_41_2 article-title: Matching methods for causal inference: a review and a look forward publication-title: Stat. Sci. doi: 10.1214/09-STS313 – volume: 129 start-page: 837 issue: 8 year: 2014 ident: e_1_3_4_3_2 article-title: Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.005119 – volume: 369 start-page: 2093 issue: 22 year: 2013 ident: e_1_3_4_9_2 article-title: Edoxaban versus warfarin in patients with atrial fibrillation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1310907 – volume: 353 start-page: i3189 year: 2016 ident: e_1_3_4_27_2 article-title: Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study publication-title: BMJ doi: 10.1136/bmj.i3189 – volume: 316 start-page: 1818 issue: 17 year: 2016 ident: e_1_3_4_17_2 article-title: Confounding by indication in clinical research publication-title: JAMA doi: 10.1001/jama.2016.16435 – volume: 20 start-page: 164 issue: 2 year: 2003 ident: e_1_3_4_11_2 article-title: Designing a research project: randomised controlled trials and their principles publication-title: Emerg. Med. J. doi: 10.1136/emj.20.2.164 – volume: 34 start-page: 173 issue: 2 year: 2019 ident: e_1_3_4_14_2 article-title: Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies publication-title: Eur. J. Epidemiol. doi: 10.1007/s10654-018-0415-7 – volume: 13 start-page: e006065 issue: 1 year: 2020 ident: e_1_3_4_35_2 article-title: Doubly robust estimation of causal effect: upping the odds of getting the right answers publication-title: Circ. Cardiovasc. Qual. Outcomes doi: 10.1161/CIRCOUTCOMES.119.006065 – volume: 5 start-page: e000953 issue: 1 year: 2019 ident: e_1_3_4_44_2 article-title: Three handy tips and a practical guide to improve your propensity score models publication-title: RMD Open doi: 10.1136/rmdopen-2019-000953 – volume: 26 start-page: 1033 issue: 9 year: 2017 ident: e_1_3_4_12_2 article-title: Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making publication-title: Pharmacoepidemiol. Drug Saf. doi: 10.1002/pds.4297 – volume: 355 start-page: i4919 year: 2016 ident: e_1_3_4_15_2 article-title: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions publication-title: BMJ doi: 10.1136/bmj.i4919 – volume: 46 start-page: 399 issue: 3 year: 2011 ident: e_1_3_4_29_2 article-title: An introduction to propensity score methods for reducing the effects of confounding in observational studies publication-title: Multivariate Behav. Res. doi: 10.1080/00273171.2011.568786 – volume: 367 start-page: l5657 year: 2019 ident: e_1_3_4_37_2 article-title: Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners publication-title: BMJ doi: 10.1136/bmj.l5657 – ident: e_1_3_4_32_2 – volume: 1 start-page: 1 issue: 1 year: 2014 ident: e_1_3_4_16_2 article-title: Confounding by indication and related concepts publication-title: Curr. Epidemiol. Rep. doi: 10.1007/s40471-013-0004-y – ident: e_1_3_4_18_2 doi: 10.2217/cer-2018-0007 – volume: 49 start-page: 2933 issue: 12 year: 2018 ident: e_1_3_4_25_2 article-title: Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients publication-title: Stroke doi: 10.1161/STROKEAHA.118.020232 – volume: 185 start-page: 65 issue: 1 year: 2017 ident: e_1_3_4_48_2 article-title: Targeted maximum likelihood estimation for causal inference in observational studies publication-title: Am. J. Epidemiol. doi: 10.1093/aje/kww165 – volume: 69 start-page: 345 issue: 3 year: 2017 ident: e_1_3_4_21_2 article-title: Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies publication-title: J. Am. Coll. Cardiol. doi: 10.1016/j.jacc.2016.10.060 – volume: 38 start-page: 350 issue: 4 year: 2011 ident: e_1_3_4_5_2 article-title: Stroke prevention in nonvalvular atrial fibrillation publication-title: Texas Heart Inst. J. – volume: 146 start-page: 857 issue: 12 year: 2007 ident: e_1_3_4_6_2 article-title: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-146-12-200706190-00007 – volume: 98 start-page: 253 issue: 3 year: 2006 ident: e_1_3_4_22_2 article-title: Indications for propensity scores and review of their use in pharmacoepidemiology publication-title: Basic Clin. Pharmacol. Toxicol. doi: 10.1111/j.1742-7843.2006.pto_293.x – volume: 356 start-page: j510 year: 2017 ident: e_1_3_4_38_2 article-title: Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study publication-title: BMJ doi: 10.1136/bmj.j510 |
| SSID | ssj0000684952 |
| Score | 2.505896 |
| SecondaryResourceType | review_article |
| Snippet | After decades of warfarin being the only oral anticoagulant (OAC) widely available for stroke prevention in atrial fibrillation, four direct OACs (apixaban,... |
| SourceID | unpaywall proquest pubmed crossref futurescience |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 603 |
| SubjectTerms | Administration, Oral Anticoagulants Anticoagulants - administration & dosage Anticoagulants - therapeutic use atrial fibrillation Atrial Fibrillation - drug therapy Atrial Fibrillation - prevention & control Bias Cardiac arrhythmia Case studies Comparative Effectiveness Research confounding by indication Humans inverse probability of treatment weighting Medical prognosis oral anticoagulants Patients Propensity Score propensity score matching Stroke Stroke - drug therapy Stroke - prevention & control Systematic review |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LSyQxEA6uHlxZRFHXWR9EWHYvNubRz5OIKOJBPCjMrclThaF71plB5i_tr9yqTqZdQb1letJ00VVJvlS-_oqQn1yV2llpE61dnqRO-6SU0MoKWQpTMRR0QbbFTX51n14Ps2FMuE0irXIxJ3YTtW0N5shPBAKXDMCJOB3_SbBqFJ6uxhIaX8gKB6iCUV0Miz7HwvIS8D8eJAj8CiWH2A4ymwKA-IlxzxAjAj-s5vLNsvQt6HnENeg97LlGVmfNWM1f1Gj033p0uUHWI5CkZ8Hzm2TJNVvk7y3m1hvkWdAJClRSAKQdW5KqxtKnBkkYjmIVmaDPPaetpz3ZnL50iVLsPm0pzEm4F6ewY_ZYfAkv6znFQ-6Q54MmNa_q4TRwQ-L0SaOM0CM-AWUAwAIwtVUPsxFyb7bJ_eXF3flVEqsxJCblbJp4VkGjZKqSpTUadtVCA3jKs0wz61NXOce8VVUBKMAzC8hDpj7lsF20AmCpkjtkuWkbt0uoZpXlSpWllhAMjitmCs9yIZg3Qls-IMcLZ9QmSpVjxYxRDVsW9F0NvqvRd0jJkwPyq-8-DhodH3UUbzxbh18LFsNHN-0v3F_H8T2pX6NxQI76v2Fk4nGLalw7gz6ygHfE87wYkO8hbHrzZFcKTMDdv_s4-tz2H5-bsUe-hljG_NA-WZ4-z9wBwKWpPuzGxD9uERan priority: 102 providerName: ProQuest – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6h7QEQoiBeCy0yEoILKY6d57Gquqo4VD2wUjlFfkLFKqnaRNXyk_orO7P2hhYocPNmbWXiTOxv7M_fALxNVaWdlTbR2hVJ5rRPKomlvJSVMDUnQRdiWxwWB_Ps03F-HEk0dBbm2v69QLT80bgzfJGCTj9TbtqNgvaRJrAxPzza_UKJ4-h4SSFXVMVYTmXQ0vy9_Y2550EQ7YgTzZ8A5n24O7SnanmhFotrk85sE2ZrcwPX5PvO0Osd8-MXJcd_Ps8jeBhhJ9sNfvIY7rj2CVwe0Up8S6wMdk5ylgzh64pbyVRr2UlLlA3HKOdMUPNess6zkZrOLlbLqlS97xiOYBS5M4yvPaVqost6yWhLPKwKYpGZn1rjLDBJ4mDLoujQN7oDiQagBWhqp74OC2LqPIX5bP_z3kESczckJkt5n3heY6HiqpaVNRpjcKERahV5rrn1maud496qukTM4LlFnCIzn6UYXFqBIFbJZzBpu9a9AKZ5bVOlqkpLdB2XKm5KzwshuDdC23QKH9ZvtTFR2JzyaywaDHCo0xvs9IY6nQh8cgrvxuqnQdHjtorihos04dea83Bbo621HzVxNDhvBIHuHIG1mMKb8W_8jmlzRrWuG7COLLGP0qIop_A8-N9onlwlDhPY-v3okH-3_eV_13wF94I_0sLSFkz6s8FtI87q9ev4lV0BknIk-A priority: 102 providerName: Unpaywall |
| Title | Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants |
| URI | http://dx.doi.org/10.2217/cer-2020-0013 https://www.ncbi.nlm.nih.gov/pubmed/32186922 https://www.proquest.com/docview/2507155332 https://www.proquest.com/docview/2379021667 https://doi.org/10.2217/cer-2020-0013 |
| UnpaywallVersion | publishedVersion |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2042-6313 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: RPM dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2042-6313 dateEnd: 20210430 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: 7X7 dateStart: 20190101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2042-6313 dateEnd: 20210430 omitProxy: true ssIdentifier: ssj0000684952 issn: 2042-6305 databaseCode: BENPR dateStart: 20190101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bixMxFD7o9kFFRPFWXUsE0RcHM8lcH1fZsgiWIhbq05BMElYomWU7Zelf8ld6TpPOWnR98KlpJzM9zJfLd5KT7wC8SVWlrZEm0doWSWa1SyqJpbyUlWhrToIuFG0xK84W2edlvrwWSTrcwRfIlz-09hKhFHT-mbLTjkRZ5NgDR9PFl-g9hUG3QqpPewaCDpwU2IyDouafzziYge4H6Y443fyNZt6DOxt_obZXarX6beqZPoQHkTOykwDyI7hl_WP4OadldE8hFWxNWpQMuecuMJIpb9gPT_EWllHCmCDFvWWdY0NcObvarYlS9b5jOPyQ283QOXaUZ4l-1ltG-9lhSQ-LrL0WCmchDCSOlCwqBp3TP9CJf7QATe0Upbn3_foJLKan3z6dJTHxQtJmKe8Tx2ssVFzVsjKtRgdaaORJRZ5rblxma2u5M6ouccJ33CDJkJnLUvQMjUAGquRTOPKdt8-BaV6bVKmq0hJxt6nibel4IQR3rdAmHcP7PRhNG1XJKTnGqkHvhLBrELuGsKPoOzmGt0P1iyDHcVNFcYBsE77tAxZuuul4D38Tu_K6EcSYc2TFYgyvh8vYCWlnRXnbbbCOLPEdpUVRjuFZaDaDeXKX9Uvg3e-GdvRv21_8j-0v4W5o4bRAdAxH_eXGvkK-1OsJ3C6X5QRGH09n86-T2HPwczGbn3z_BUmrGME |
| linkProvider | Future Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VcigIIRBQAgWMxOPCql57nweEEFCltFQcWim3xU9AinZDkyjKX-LAb2RmvbulEu2tNyfxJqPMeDwz_vwNwItYFdpZaSOtXRYlTvuokDhKc1kIU3IidCG0xVE2Pkk-T9LJBvzp78IQrLL3ia2jto2hGvmuoMAlxeBEvJv9iqhrFJ2u9i00glkcuPUKU7b52_2PqN-XQux9Ov4wjrquApFJYr6IPC9xUHBVysIajdmh0BgEZGmqufWJK53j3qoyx93Mc4s7qEx8EmPaYwWGV0ri916D64nkCXH155N8qOnwrMB8gw4uBN16yXAtBVpPgYH_rnGnaJOCLnLH8tw2eCvwh3R73v9i3Zuwtaxnar1S0-k_-9_eHbjdBa7sfbC0u7Dh6nvw-yvV8mvCdbA5EWIyDIBbdCZTtWU_awJ9OEZdawIf-Jo1ng3gdrZqC7M0fdEw9IGU-zPM0D01e6K39ZrRoXqoK-KQmTO2chawKJ27Zh1t0Q_6BaIdQAlQ1EZ9X04J63MfTq5ETw9gs25q9xCY5qWNlSoKjUrjLlbc5J5nQnBvhLbxCN70yqhMR41OHTqmFaZIpLsKdVeR7ggCKEfwapg-C5wgF00U5zRbhVc9auKih3Z69VedP5lXZ9Y_gufDx-gJ6HhH1a5Z4hyZ438UZ1k-gu1gNoN4sm09JvDp14MdXS77o8vFeAZb4-Mvh9Xh_tHBY7gR7JpqUzuwuThduicYqi3003Z9MPh21QvyL_LLUhE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1baxNBFD7UCl4QUbxFq47g5cUlszN7fRARa2itlD5YyNs6VxXCbmwSQv6SP8Ff5zk7u1sLtm99mySzySHnfuabcwBexqrQzkobae2yKHHaR4XEVZrLQpiSU0MXQlscZnvHyedpOt2CP_1dGIJV9jaxNdS2MVQjHwsKXFIMTsTYd7CIo93J-_mviCZI0UlrP04jiMiB26wxfVu8299FXr8SYvLp68e9qJswEJkk5svI8xIXBVelLKzRmCkKjQFBlqaaW5-40jnurSpz9GyeW_SmMvFJjCmQFRhqKYnfewWu5jKRBCfLp_lQ3-FZgbkHHWIIugGToV6FFp8Ck4CxcScon4IudcfyjEu8FXqJdP7vf3HvTbi-qudqs1az2T--cHIHbndBLPsQpO4ubLn6Hvw-orp-TRgPtqDmmAyD4RapyVRt2c-aACCO0QSb0Bt8wxrPBqA7W7dFWtq-bBjaQ6oDMMzWPQ1-orf1htEBe6gx4pKZ087lLOBSOtPNuhZGP-gXqAUBUoCkNur7aka4n_twfCl8egDbdVO7R8A0L22sVFFoiYLoYsVN7nkmBPdGaBuP4G3PjMp0bdJpWseswnSJeFch7yriHcEB5QheD9vnoT_IeRvFGc5W4VWPoDjvoZ2e_VVnWxbVqSaM4MXwMVoFOupRtWtWuEfm-B_FWZaP4GEQm4E82Y4hE_j0m0GOLqb98cVkPIdrqIrVl_3DgydwI4g1lal2YHt5snJPMWpb6metejD4dtn6-Bevs1ZM |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwEB6h7QEQoiBeCy0yEoILKY6d57Gquqo4VD2wUjlFfkLFKqnaRNXyk_orO7P2hhYocPNmbWXiTOxv7M_fALxNVaWdlTbR2hVJ5rRPKomlvJSVMDUnQRdiWxwWB_Ps03F-HEk0dBbm2v69QLT80bgzfJGCTj9TbtqNgvaRJrAxPzza_UKJ4-h4SSFXVMVYTmXQ0vy9_Y2550EQ7YgTzZ8A5n24O7SnanmhFotrk85sE2ZrcwPX5PvO0Osd8-MXJcd_Ps8jeBhhJ9sNfvIY7rj2CVwe0Up8S6wMdk5ylgzh64pbyVRr2UlLlA3HKOdMUPNess6zkZrOLlbLqlS97xiOYBS5M4yvPaVqost6yWhLPKwKYpGZn1rjLDBJ4mDLoujQN7oDiQagBWhqp74OC2LqPIX5bP_z3kESczckJkt5n3heY6HiqpaVNRpjcKERahV5rrn1maud496qukTM4LlFnCIzn6UYXFqBIFbJZzBpu9a9AKZ5bVOlqkpLdB2XKm5KzwshuDdC23QKH9ZvtTFR2JzyaywaDHCo0xvs9IY6nQh8cgrvxuqnQdHjtorihos04dea83Bbo621HzVxNDhvBIHuHIG1mMKb8W_8jmlzRrWuG7COLLGP0qIop_A8-N9onlwlDhPY-v3okH-3_eV_13wF94I_0sLSFkz6s8FtI87q9ev4lV0BknIk-A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Propensity+score+matching+and+inverse+probability+of+treatment+weighting+to+address+confounding+by+indication+in+comparative+effectiveness+research+of+oral+anticoagulants&rft.jtitle=Journal+of+comparative+effectiveness+research&rft.date=2020-06-01&rft.pub=Future+Medicine+Ltd&rft.issn=2042-6305&rft.eissn=2042-6313&rft.volume=9&rft.issue=9&rft.spage=603&rft.epage=614&rft_id=info:doi/10.2217%2Fcer-2020-0013&rft.externalDocID=10_2217_cer_2020_0013 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2042-6305&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2042-6305&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2042-6305&client=summon |